Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Editas Medicine Inc EDIT

Healthcare Biotechnology
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9... see more

Recent & Breaking News (NDAQ:EDIT)

Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing

GlobeNewswire July 7, 2020

Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares

GlobeNewswire June 26, 2020

Editas Medicine Announces Pricing of Offering of Common Stock

GlobeNewswire June 23, 2020

Editas Medicine Announces Offering of Common Stock

GlobeNewswire June 23, 2020

Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease

GlobeNewswire June 12, 2020

Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies

GlobeNewswire May 15, 2020

Editas Medicine Announces First Quarter 2020 Results and Update

GlobeNewswire May 7, 2020

Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update

GlobeNewswire April 30, 2020

Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers

GlobeNewswire April 29, 2020

Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

GlobeNewswire March 4, 2020

Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update

GlobeNewswire February 26, 2020

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update

GlobeNewswire February 19, 2020

Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference

GlobeNewswire January 13, 2020

Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

GlobeNewswire January 13, 2020

Editas Medicine Reports Inducement Grants to New Chief Financial Officer

GlobeNewswire January 10, 2020

Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth

GlobeNewswire January 9, 2020

Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2020

Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

GlobeNewswire December 9, 2019

Editas Medicine Announces Third Quarter 2019 Results and Update

GlobeNewswire November 12, 2019

Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases

GlobeNewswire November 12, 2019